TP53 gene implications in prostate cancer evolution: potential role in tumor classification.
adenocarcinoma
biomarkers
microRNAs
prostatic neoplasms
Journal
Medicine and pharmacy reports
ISSN: 2668-0572
Titre abrégé: Med Pharm Rep
Pays: Romania
ID NLM: 101742144
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
14
05
2023
revised:
01
07
2023
accepted:
13
07
2023
medline:
16
11
2023
pubmed:
16
11
2023
entrez:
16
11
2023
Statut:
ppublish
Résumé
Prostate adenocarcinoma (PRAD) is a complex disease that can be driven by alterations in both coding and noncoding genes. Recent research has identified coding and non-coding genes that are considered to play important roles in prostate cancer evolution and which may be used as biomarkers for disease diagnosis, prognosis, and treatment. TP53 is a critical hub gene in prostate cancer. Advanced studies have demonstrated the crosstalk between coding and non-coding RNAs, particularly microRNAs (miRNAs). In this study, we investigated the roundabout of TP53 and their regulatory miRNAs (miR-15a-5p, miR-34a-5p, and miR-141-3p) based on the TCGA data set. We validated an additional patient cohort of 28 matched samples of patients with PRAD at tissue and plasma level. Therefore, using the UALCAN online database, we evaluated the expression level in PRAD of these genes revealing overexpression of TP53. qRT-PCR validation step endorsed the expression level for these genes. Additionally, we evaluated the expression level of the four key miRNAs (miR-15a-5p, miR-34a-5p, and miR-141-3p) interconnected as a network at tissue and plasma levels. Through these results, we demonstrated the essential function of TP53 and its associated miRNAs that play a significant role in tumor control, highlighting miRNAs' potential as future therapeutic targets and biomarkers with important implications in managing prostate cancer.
Sections du résumé
Background and aims
UNASSIGNED
Prostate adenocarcinoma (PRAD) is a complex disease that can be driven by alterations in both coding and noncoding genes. Recent research has identified coding and non-coding genes that are considered to play important roles in prostate cancer evolution and which may be used as biomarkers for disease diagnosis, prognosis, and treatment. TP53 is a critical hub gene in prostate cancer. Advanced studies have demonstrated the crosstalk between coding and non-coding RNAs, particularly microRNAs (miRNAs).
Methods
UNASSIGNED
In this study, we investigated the roundabout of TP53 and their regulatory miRNAs (miR-15a-5p, miR-34a-5p, and miR-141-3p) based on the TCGA data set. We validated an additional patient cohort of 28 matched samples of patients with PRAD at tissue and plasma level.
Results
UNASSIGNED
Therefore, using the UALCAN online database, we evaluated the expression level in PRAD of these genes revealing overexpression of TP53. qRT-PCR validation step endorsed the expression level for these genes. Additionally, we evaluated the expression level of the four key miRNAs (miR-15a-5p, miR-34a-5p, and miR-141-3p) interconnected as a network at tissue and plasma levels.
Conclusions
UNASSIGNED
Through these results, we demonstrated the essential function of TP53 and its associated miRNAs that play a significant role in tumor control, highlighting miRNAs' potential as future therapeutic targets and biomarkers with important implications in managing prostate cancer.
Identifiants
pubmed: 37970196
doi: 10.15386/mpr-2639
pii: cm-96-384
pmc: PMC10642740
doi:
Types de publication
Journal Article
Langues
eng
Pagination
384-391Références
Oncotarget. 2017 Jan 3;8(1):624-643
pubmed: 27880943
Cancer Cell Int. 2020 Aug 15;20:394
pubmed: 32821247
Int Urol Nephrol. 2018 Sep;50(9):1619-1626
pubmed: 30014459
Oncotarget. 2016 May 24;7(21):30760-71
pubmed: 27120795
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Biomark Med. 2019 Jul;13(10):831-840
pubmed: 31116024
Cancers (Basel). 2020 Jan 27;12(2):
pubmed: 32012717
Aging (Albany NY). 2019 Dec 29;11(24):12754-12772
pubmed: 31895690
Front Oncol. 2021 Feb 04;10:620306
pubmed: 33614501
J Urol. 2014 Jul;192(1):252-9
pubmed: 24518785
Nat Med. 2008 Nov;14(11):1271-7
pubmed: 18931683
Medicine (Baltimore). 2020 May 29;99(22):e19993
pubmed: 32481368
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Cancer Res. 2023 Sep 1;83(17):2970-2984
pubmed: 37352385
Cancer Biomark. 2018;22(1):19-28
pubmed: 29562494
Cell Death Dis. 2017 Oct 12;8(10):e3100
pubmed: 29022903
Biochem Biophys Res Commun. 2017 Jan 22;482(4):1381-1386
pubmed: 27956179
J Exp Clin Cancer Res. 2017 Dec 4;36(1):173
pubmed: 29202848
Sci Rep. 2020 Jan 14;10(1):227
pubmed: 31937854
Cancer Inform. 2022 Apr 2;21:11769351221087046
pubmed: 35392296
Pharmaceutics. 2021 Mar 13;13(3):
pubmed: 33805590
Sci Rep. 2019 Jan 23;9(1):386
pubmed: 30674952
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7
pubmed: 24297251
Biomed Pharmacother. 2018 Aug;104:637-644
pubmed: 29803177
J Cancer. 2013 May 09;4(5):350-7
pubmed: 23781281
Transl Androl Urol. 2021 Apr;10(4):1754-1768
pubmed: 33968663
Cell Death Differ. 2010 Jun;17(6):901-11
pubmed: 20379196
J Cell Biochem. 2017 Jan;118(1):7-14
pubmed: 27216701
Cancers (Basel). 2020 Oct 20;12(10):
pubmed: 33092068
Front Cell Dev Biol. 2021 Mar 08;9:640587
pubmed: 33763422
PLoS One. 2015 Jul 15;10(7):e0132767
pubmed: 26177460
BMC Med Genomics. 2020 Sep 18;13(Suppl 8):129
pubmed: 32948204
J Pers Med. 2021 May 26;11(6):
pubmed: 34073426
Mol Cell Biochem. 2013 Sep;381(1-2):61-8
pubmed: 23881244
Nucleic Acids Res. 2016 Jul 8;44(W1):W135-41
pubmed: 27105848
Biochim Biophys Acta Mol Cell Res. 2023 Oct;1870(7):119527
pubmed: 37356458
Cancer Biother Radiopharm. 2019 Sep;34(7):472-479
pubmed: 31135177
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):482-491
pubmed: 33214693
Biotechnol Lett. 2021 May;43(5):981-994
pubmed: 33515341